Global Single-Domain Antibody Therapeutics Supply, Demand and Key Producers, 2026-2032
The global Single-Domain Antibody Therapeutics market size is expected to reach $ 1132 million by 2032, rising at a market growth of 11.6% CAGR during the forecast period (2026-2032).
Single-domain antibody therapeutics are biologic treatments developed around a single antibody variable domain, including VHH, human VH, human VL, and VNAR domains. These domains can be linked, fused, conjugated, or assembled into monovalent, bivalent, multivalent, multispecific, Fc-fusion, and albumin-binding half-life-extended formats. Major therapeutic applications include hematological disorders, autoimmune and inflammatory diseases, oncology, respiratory diseases, and infectious diseases. Representative commercialized products include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab developed by Alphamab Oncology, while a growing number of multivalent, multispecific, and inhaled single-domain antibody candidates remain in clinical development. Key upstream inputs include antibody discovery and display libraries, engineered production cell lines, culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, linkers, sterile filling components, vials or prefilled syringes, and cold-chain packaging materials. Downstream users and treatment settings include pharmaceutical and biotechnology companies, hospitals, specialty treatment centers, and clinical departments specializing in hematology, rheumatology, oncology, and respiratory medicine. Based on commercial drug shipments at ex-factory prices, global nominal production capacity in 2025 is estimated at approximately 1.25 million units, with actual sales volume of around 728,000 units, an average ex-factory price of approximately USD 690 per unit, and an overall industry gross margin of about 70%?85%.
The single-domain antibody therapeutics market has progressed from early platform validation toward a stage where commercial products and clinical pipelines coexist. Approved therapies have established clinical use in hematological disorders, autoimmune diseases, and oncology, although the total number of marketed products remains considerably smaller than that of conventional full-length monoclonal antibodies. The competitive landscape consists of a limited number of mature platform owners and a broader group of clinical-stage biotechnology companies. Leading participants benefit from antibody discovery capabilities, molecular engineering expertise, clinical development experience, and global commercialization infrastructure. Companies in China, the United States, Europe, and Japan are also developing differentiated strategies in subcutaneous administration, inhaled delivery, multispecific formats, and local treatment. Future development is expected to move further toward multivalent, multispecific, half-life-extended, and tissue-targeted formats. The small size and relatively simple structure of single-domain antibodies make them suitable for linking multiple binding domains, albumin-binding modules, Fc regions, and functional effector units within one molecule. This enables developers to adjust potency, pharmacokinetics, tissue distribution, and dosing frequency. Advances in protein engineering may expand the modality from single-target blockade to dual-pathway inhibition, receptor agonism, immune-cell engagement, and targeted payload delivery. Inhaled, local, and mucosal administration may also become increasingly important, particularly in respiratory, ophthalmic, gastrointestinal, and localized inflammatory diseases. Market growth is being supported by unmet medical needs, the tissue penetration limitations of conventional antibodies, rising demand for multispecific biologics, and the development of more convenient administration routes. Single-domain antibodies can potentially access tissue compartments that are less accessible to full-length antibodies and may be produced through microbial or mammalian expression systems, providing flexibility for concentrated formulations, subcutaneous dosing, and local delivery. Acquisitions, licensing agreements, and co-development partnerships involving large pharmaceutical companies are also accelerating clinical development and global registration. As more candidates reach late-stage trials and demonstrate clear therapeutic differentiation, the modality may expand further across autoimmune disease, inflammation, oncology, respiratory disease, and rare disease treatment. The main barriers include short natural half-life, rapid renal clearance, potential immunogenicity associated with certain animal-derived sequences, and the increasing complexity of multidomain molecules. Developers often use albumin-binding domains, Fc fusion, or other half-life-extension technologies to improve systemic exposure, but these modifications may reduce some of the size and tissue penetration advantages of standalone domains. Multivalent and multispecific formats can also create challenges involving aggregation, stability, expression yield, analytical characterization, and batch consistency. From a commercial perspective, single-domain therapeutics compete with conventional monoclonal antibodies, biosimilars, small-molecule drugs, and alternative antibody formats. Broader adoption will therefore depend on demonstrating clear advantages in efficacy, safety, administration convenience, or treatment economics.
This report studies the global Single-Domain Antibody Therapeutics production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Single-Domain Antibody Therapeutics and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Single-Domain Antibody Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Single-Domain Antibody Therapeutics total production and demand, 2021-2032, (K Units)
Global Single-Domain Antibody Therapeutics total production value, 2021-2032, (USD Million)
Global Single-Domain Antibody Therapeutics production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Single-Domain Antibody Therapeutics consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Single-Domain Antibody Therapeutics domestic production, consumption, key domestic manufacturers and share
Global Single-Domain Antibody Therapeutics production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Single-Domain Antibody Therapeutics production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Single-Domain Antibody Therapeutics production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Single-Domain Antibody Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Taisho Pharmaceutical, Alphamab Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Single-Domain Antibody Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Single-Domain Antibody Therapeutics Market, By Region:
1. How big is the global Single-Domain Antibody Therapeutics market?
2. What is the demand of the global Single-Domain Antibody Therapeutics market?
3. What is the year over year growth of the global Single-Domain Antibody Therapeutics market?
4. What is the production and production value of the global Single-Domain Antibody Therapeutics market?
5. Who are the key producers in the global Single-Domain Antibody Therapeutics market?
6. What are the growth factors driving the market demand?
Single-domain antibody therapeutics are biologic treatments developed around a single antibody variable domain, including VHH, human VH, human VL, and VNAR domains. These domains can be linked, fused, conjugated, or assembled into monovalent, bivalent, multivalent, multispecific, Fc-fusion, and albumin-binding half-life-extended formats. Major therapeutic applications include hematological disorders, autoimmune and inflammatory diseases, oncology, respiratory diseases, and infectious diseases. Representative commercialized products include Sanofi's Cablivi, Taisho Pharmaceutical's Nanozora, and Envafolimab developed by Alphamab Oncology, while a growing number of multivalent, multispecific, and inhaled single-domain antibody candidates remain in clinical development. Key upstream inputs include antibody discovery and display libraries, engineered production cell lines, culture media, feeds, single-use bioreactor consumables, chromatography resins, ultrafiltration membranes, buffers, linkers, sterile filling components, vials or prefilled syringes, and cold-chain packaging materials. Downstream users and treatment settings include pharmaceutical and biotechnology companies, hospitals, specialty treatment centers, and clinical departments specializing in hematology, rheumatology, oncology, and respiratory medicine. Based on commercial drug shipments at ex-factory prices, global nominal production capacity in 2025 is estimated at approximately 1.25 million units, with actual sales volume of around 728,000 units, an average ex-factory price of approximately USD 690 per unit, and an overall industry gross margin of about 70%?85%.
The single-domain antibody therapeutics market has progressed from early platform validation toward a stage where commercial products and clinical pipelines coexist. Approved therapies have established clinical use in hematological disorders, autoimmune diseases, and oncology, although the total number of marketed products remains considerably smaller than that of conventional full-length monoclonal antibodies. The competitive landscape consists of a limited number of mature platform owners and a broader group of clinical-stage biotechnology companies. Leading participants benefit from antibody discovery capabilities, molecular engineering expertise, clinical development experience, and global commercialization infrastructure. Companies in China, the United States, Europe, and Japan are also developing differentiated strategies in subcutaneous administration, inhaled delivery, multispecific formats, and local treatment. Future development is expected to move further toward multivalent, multispecific, half-life-extended, and tissue-targeted formats. The small size and relatively simple structure of single-domain antibodies make them suitable for linking multiple binding domains, albumin-binding modules, Fc regions, and functional effector units within one molecule. This enables developers to adjust potency, pharmacokinetics, tissue distribution, and dosing frequency. Advances in protein engineering may expand the modality from single-target blockade to dual-pathway inhibition, receptor agonism, immune-cell engagement, and targeted payload delivery. Inhaled, local, and mucosal administration may also become increasingly important, particularly in respiratory, ophthalmic, gastrointestinal, and localized inflammatory diseases. Market growth is being supported by unmet medical needs, the tissue penetration limitations of conventional antibodies, rising demand for multispecific biologics, and the development of more convenient administration routes. Single-domain antibodies can potentially access tissue compartments that are less accessible to full-length antibodies and may be produced through microbial or mammalian expression systems, providing flexibility for concentrated formulations, subcutaneous dosing, and local delivery. Acquisitions, licensing agreements, and co-development partnerships involving large pharmaceutical companies are also accelerating clinical development and global registration. As more candidates reach late-stage trials and demonstrate clear therapeutic differentiation, the modality may expand further across autoimmune disease, inflammation, oncology, respiratory disease, and rare disease treatment. The main barriers include short natural half-life, rapid renal clearance, potential immunogenicity associated with certain animal-derived sequences, and the increasing complexity of multidomain molecules. Developers often use albumin-binding domains, Fc fusion, or other half-life-extension technologies to improve systemic exposure, but these modifications may reduce some of the size and tissue penetration advantages of standalone domains. Multivalent and multispecific formats can also create challenges involving aggregation, stability, expression yield, analytical characterization, and batch consistency. From a commercial perspective, single-domain therapeutics compete with conventional monoclonal antibodies, biosimilars, small-molecule drugs, and alternative antibody formats. Broader adoption will therefore depend on demonstrating clear advantages in efficacy, safety, administration convenience, or treatment economics.
This report studies the global Single-Domain Antibody Therapeutics production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Single-Domain Antibody Therapeutics and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Single-Domain Antibody Therapeutics that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Single-Domain Antibody Therapeutics total production and demand, 2021-2032, (K Units)
Global Single-Domain Antibody Therapeutics total production value, 2021-2032, (USD Million)
Global Single-Domain Antibody Therapeutics production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Units), (based on production site)
Global Single-Domain Antibody Therapeutics consumption by region & country, CAGR, 2021-2032 & (K Units)
U.S. VS China: Single-Domain Antibody Therapeutics domestic production, consumption, key domestic manufacturers and share
Global Single-Domain Antibody Therapeutics production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Units)
Global Single-Domain Antibody Therapeutics production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
Global Single-Domain Antibody Therapeutics production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Units)
This report profiles key players in the global Single-Domain Antibody Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi, Taisho Pharmaceutical, Alphamab Oncology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Single-Domain Antibody Therapeutics market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Single-Domain Antibody Therapeutics Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Cablivi
- Nanozora
- Envafolimab
- Subcutaneous Injection
- Intravenous Injection
- Other
- Online Sales
- Offline Sales
- Hospital
- Clinic
- Others
- Sanofi
- Taisho Pharmaceutical
- Alphamab Oncology
1. How big is the global Single-Domain Antibody Therapeutics market?
2. What is the demand of the global Single-Domain Antibody Therapeutics market?
3. What is the year over year growth of the global Single-Domain Antibody Therapeutics market?
4. What is the production and production value of the global Single-Domain Antibody Therapeutics market?
5. Who are the key producers in the global Single-Domain Antibody Therapeutics market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Single-Domain Antibody Therapeutics Introduction
1.2 World Single-Domain Antibody Therapeutics Supply & Forecast
1.2.1 World Single-Domain Antibody Therapeutics Production Value (2021 & 2025 & 2032)
1.2.2 World Single-Domain Antibody Therapeutics Production (2021-2032)
1.2.3 World Single-Domain Antibody Therapeutics Pricing Trends (2021-2032)
1.3 World Single-Domain Antibody Therapeutics Production by Region (Based on Production Site)
1.3.1 World Single-Domain Antibody Therapeutics Production Value by Region (2021-2032)
1.3.2 World Single-Domain Antibody Therapeutics Production by Region (2021-2032)
1.3.3 World Single-Domain Antibody Therapeutics Average Price by Region (2021-2032)
1.3.4 North America Single-Domain Antibody Therapeutics Production (2021-2032)
1.3.5 Europe Single-Domain Antibody Therapeutics Production (2021-2032)
1.3.6 China Single-Domain Antibody Therapeutics Production (2021-2032)
1.3.7 Japan Single-Domain Antibody Therapeutics Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Single-Domain Antibody Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Single-Domain Antibody Therapeutics Major Market Trends
2 DEMAND SUMMARY
2.1 World Single-Domain Antibody Therapeutics Demand (2021-2032)
2.2 World Single-Domain Antibody Therapeutics Consumption by Region
2.2.1 World Single-Domain Antibody Therapeutics Consumption by Region (2021-2026)
2.2.2 World Single-Domain Antibody Therapeutics Consumption Forecast by Region (2027-2032)
2.3 United States Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.4 China Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.5 Europe Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.6 Japan Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.7 South Korea Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.8 ASEAN Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.9 India Single-Domain Antibody Therapeutics Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Single-Domain Antibody Therapeutics Production Value by Manufacturer (2021-2026)
3.2 World Single-Domain Antibody Therapeutics Production by Manufacturer (2021-2026)
3.3 World Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026)
3.4 Single-Domain Antibody Therapeutics Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Single-Domain Antibody Therapeutics Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Single-Domain Antibody Therapeutics in 2025
3.5.3 Global Concentration Ratios (CR8) for Single-Domain Antibody Therapeutics in 2025
3.6 Single-Domain Antibody Therapeutics Market: Overall Company Footprint Analysis
3.6.1 Single-Domain Antibody Therapeutics Market: Region Footprint
3.6.2 Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
3.6.3 Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Single-Domain Antibody Therapeutics Production Value Comparison
4.1.1 United States VS China: Single-Domain Antibody Therapeutics Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Single-Domain Antibody Therapeutics Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Single-Domain Antibody Therapeutics Production Comparison
4.2.1 United States VS China: Single-Domain Antibody Therapeutics Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Single-Domain Antibody Therapeutics Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Single-Domain Antibody Therapeutics Consumption Comparison
4.3.1 United States VS China: Single-Domain Antibody Therapeutics Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Single-Domain Antibody Therapeutics Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Single-Domain Antibody Therapeutics Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Single-Domain Antibody Therapeutics Production Value (2021-2026)
4.4.3 United States Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026)
4.5 China Based Single-Domain Antibody Therapeutics Manufacturers and Market Share
4.5.1 China Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Single-Domain Antibody Therapeutics Production Value (2021-2026)
4.5.3 China Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026)
4.6 Rest of World Based Single-Domain Antibody Therapeutics Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Single-Domain Antibody Therapeutics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Cablivi
5.2.2 Nanozora
5.2.3 Envafolimab
5.3 Market Segment by Type
5.3.1 World Single-Domain Antibody Therapeutics Production by Type (2021-2032)
5.3.2 World Single-Domain Antibody Therapeutics Production Value by Type (2021-2032)
5.3.3 World Single-Domain Antibody Therapeutics Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.1 World Single-Domain Antibody Therapeutics Market Size Overview by Administration Route: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Administration Route
6.2.1 Subcutaneous Injection
6.2.2 Intravenous Injection
6.2.3 Other
6.3 Market Segment by Administration Route
6.3.1 World Single-Domain Antibody Therapeutics Production by Administration Route (2021-2032)
6.3.2 World Single-Domain Antibody Therapeutics Production Value by Administration Route (2021-2032)
6.3.3 World Single-Domain Antibody Therapeutics Average Price by Administration Route (2021-2032)
7 MARKET ANALYSIS BY SALES CHANNELS
7.1 World Single-Domain Antibody Therapeutics Market Size Overview by Sales Channels: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Sales Channels
7.2.1 Online Sales
7.2.2 Offline Sales
7.3 Market Segment by Sales Channels
7.3.1 World Single-Domain Antibody Therapeutics Production by Sales Channels (2021-2032)
7.3.2 World Single-Domain Antibody Therapeutics Production Value by Sales Channels (2021-2032)
7.3.3 World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Single-Domain Antibody Therapeutics Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Single-Domain Antibody Therapeutics Production by Application (2021-2032)
8.3.2 World Single-Domain Antibody Therapeutics Production Value by Application (2021-2032)
8.3.3 World Single-Domain Antibody Therapeutics Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Sanofi
9.1.1 Sanofi Details
9.1.2 Sanofi Major Business
9.1.3 Sanofi Single-Domain Antibody Therapeutics Product and Services
9.1.4 Sanofi Single-Domain Antibody Therapeutics Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Sanofi Recent Developments/Updates
9.1.6 Sanofi Competitive Strengths & Weaknesses
9.2 Taisho Pharmaceutical
9.2.1 Taisho Pharmaceutical Details
9.2.2 Taisho Pharmaceutical Major Business
9.2.3 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
9.2.4 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Taisho Pharmaceutical Recent Developments/Updates
9.2.6 Taisho Pharmaceutical Competitive Strengths & Weaknesses
9.3 Alphamab Oncology
9.3.1 Alphamab Oncology Details
9.3.2 Alphamab Oncology Major Business
9.3.3 Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
9.3.4 Alphamab Oncology Single-Domain Antibody Therapeutics Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Alphamab Oncology Recent Developments/Updates
9.3.6 Alphamab Oncology Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Single-Domain Antibody Therapeutics Industry Chain
10.2 Single-Domain Antibody Therapeutics Upstream Analysis
10.2.1 Single-Domain Antibody Therapeutics Core Raw Materials
10.2.2 Main Manufacturers of Single-Domain Antibody Therapeutics Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Single-Domain Antibody Therapeutics Production Mode
10.6 Single-Domain Antibody Therapeutics Procurement Model
10.7 Single-Domain Antibody Therapeutics Industry Sales Model and Sales Channels
10.7.1 Single-Domain Antibody Therapeutics Sales Model
10.7.2 Single-Domain Antibody Therapeutics Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Single-Domain Antibody Therapeutics Introduction
1.2 World Single-Domain Antibody Therapeutics Supply & Forecast
1.2.1 World Single-Domain Antibody Therapeutics Production Value (2021 & 2025 & 2032)
1.2.2 World Single-Domain Antibody Therapeutics Production (2021-2032)
1.2.3 World Single-Domain Antibody Therapeutics Pricing Trends (2021-2032)
1.3 World Single-Domain Antibody Therapeutics Production by Region (Based on Production Site)
1.3.1 World Single-Domain Antibody Therapeutics Production Value by Region (2021-2032)
1.3.2 World Single-Domain Antibody Therapeutics Production by Region (2021-2032)
1.3.3 World Single-Domain Antibody Therapeutics Average Price by Region (2021-2032)
1.3.4 North America Single-Domain Antibody Therapeutics Production (2021-2032)
1.3.5 Europe Single-Domain Antibody Therapeutics Production (2021-2032)
1.3.6 China Single-Domain Antibody Therapeutics Production (2021-2032)
1.3.7 Japan Single-Domain Antibody Therapeutics Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Single-Domain Antibody Therapeutics Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Single-Domain Antibody Therapeutics Major Market Trends
2 DEMAND SUMMARY
2.1 World Single-Domain Antibody Therapeutics Demand (2021-2032)
2.2 World Single-Domain Antibody Therapeutics Consumption by Region
2.2.1 World Single-Domain Antibody Therapeutics Consumption by Region (2021-2026)
2.2.2 World Single-Domain Antibody Therapeutics Consumption Forecast by Region (2027-2032)
2.3 United States Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.4 China Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.5 Europe Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.6 Japan Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.7 South Korea Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.8 ASEAN Single-Domain Antibody Therapeutics Consumption (2021-2032)
2.9 India Single-Domain Antibody Therapeutics Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Single-Domain Antibody Therapeutics Production Value by Manufacturer (2021-2026)
3.2 World Single-Domain Antibody Therapeutics Production by Manufacturer (2021-2026)
3.3 World Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026)
3.4 Single-Domain Antibody Therapeutics Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Single-Domain Antibody Therapeutics Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Single-Domain Antibody Therapeutics in 2025
3.5.3 Global Concentration Ratios (CR8) for Single-Domain Antibody Therapeutics in 2025
3.6 Single-Domain Antibody Therapeutics Market: Overall Company Footprint Analysis
3.6.1 Single-Domain Antibody Therapeutics Market: Region Footprint
3.6.2 Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
3.6.3 Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Single-Domain Antibody Therapeutics Production Value Comparison
4.1.1 United States VS China: Single-Domain Antibody Therapeutics Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Single-Domain Antibody Therapeutics Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Single-Domain Antibody Therapeutics Production Comparison
4.2.1 United States VS China: Single-Domain Antibody Therapeutics Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Single-Domain Antibody Therapeutics Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Single-Domain Antibody Therapeutics Consumption Comparison
4.3.1 United States VS China: Single-Domain Antibody Therapeutics Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Single-Domain Antibody Therapeutics Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Single-Domain Antibody Therapeutics Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Single-Domain Antibody Therapeutics Production Value (2021-2026)
4.4.3 United States Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026)
4.5 China Based Single-Domain Antibody Therapeutics Manufacturers and Market Share
4.5.1 China Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Single-Domain Antibody Therapeutics Production Value (2021-2026)
4.5.3 China Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026)
4.6 Rest of World Based Single-Domain Antibody Therapeutics Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Single-Domain Antibody Therapeutics Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Cablivi
5.2.2 Nanozora
5.2.3 Envafolimab
5.3 Market Segment by Type
5.3.1 World Single-Domain Antibody Therapeutics Production by Type (2021-2032)
5.3.2 World Single-Domain Antibody Therapeutics Production Value by Type (2021-2032)
5.3.3 World Single-Domain Antibody Therapeutics Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY ADMINISTRATION ROUTE
6.1 World Single-Domain Antibody Therapeutics Market Size Overview by Administration Route: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Administration Route
6.2.1 Subcutaneous Injection
6.2.2 Intravenous Injection
6.2.3 Other
6.3 Market Segment by Administration Route
6.3.1 World Single-Domain Antibody Therapeutics Production by Administration Route (2021-2032)
6.3.2 World Single-Domain Antibody Therapeutics Production Value by Administration Route (2021-2032)
6.3.3 World Single-Domain Antibody Therapeutics Average Price by Administration Route (2021-2032)
7 MARKET ANALYSIS BY SALES CHANNELS
7.1 World Single-Domain Antibody Therapeutics Market Size Overview by Sales Channels: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Sales Channels
7.2.1 Online Sales
7.2.2 Offline Sales
7.3 Market Segment by Sales Channels
7.3.1 World Single-Domain Antibody Therapeutics Production by Sales Channels (2021-2032)
7.3.2 World Single-Domain Antibody Therapeutics Production Value by Sales Channels (2021-2032)
7.3.3 World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Single-Domain Antibody Therapeutics Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospital
8.2.2 Clinic
8.2.3 Others
8.3 Market Segment by Application
8.3.1 World Single-Domain Antibody Therapeutics Production by Application (2021-2032)
8.3.2 World Single-Domain Antibody Therapeutics Production Value by Application (2021-2032)
8.3.3 World Single-Domain Antibody Therapeutics Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Sanofi
9.1.1 Sanofi Details
9.1.2 Sanofi Major Business
9.1.3 Sanofi Single-Domain Antibody Therapeutics Product and Services
9.1.4 Sanofi Single-Domain Antibody Therapeutics Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Sanofi Recent Developments/Updates
9.1.6 Sanofi Competitive Strengths & Weaknesses
9.2 Taisho Pharmaceutical
9.2.1 Taisho Pharmaceutical Details
9.2.2 Taisho Pharmaceutical Major Business
9.2.3 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
9.2.4 Taisho Pharmaceutical Single-Domain Antibody Therapeutics Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Taisho Pharmaceutical Recent Developments/Updates
9.2.6 Taisho Pharmaceutical Competitive Strengths & Weaknesses
9.3 Alphamab Oncology
9.3.1 Alphamab Oncology Details
9.3.2 Alphamab Oncology Major Business
9.3.3 Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
9.3.4 Alphamab Oncology Single-Domain Antibody Therapeutics Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Alphamab Oncology Recent Developments/Updates
9.3.6 Alphamab Oncology Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Single-Domain Antibody Therapeutics Industry Chain
10.2 Single-Domain Antibody Therapeutics Upstream Analysis
10.2.1 Single-Domain Antibody Therapeutics Core Raw Materials
10.2.2 Main Manufacturers of Single-Domain Antibody Therapeutics Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Single-Domain Antibody Therapeutics Production Mode
10.6 Single-Domain Antibody Therapeutics Procurement Model
10.7 Single-Domain Antibody Therapeutics Industry Sales Model and Sales Channels
10.7.1 Single-Domain Antibody Therapeutics Sales Model
10.7.2 Single-Domain Antibody Therapeutics Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Single-Domain Antibody Therapeutics Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Single-Domain Antibody Therapeutics Production Value by Region (2021-2026) & (USD Million)
Table 3. World Single-Domain Antibody Therapeutics Production Value by Region (2027-2032) & (USD Million)
Table 4. World Single-Domain Antibody Therapeutics Production Value Market Share by Region (2021-2026)
Table 5. World Single-Domain Antibody Therapeutics Production Value Market Share by Region (2027-2032)
Table 6. World Single-Domain Antibody Therapeutics Production by Region (2021-2026) & (K Units)
Table 7. World Single-Domain Antibody Therapeutics Production by Region (2027-2032) & (K Units)
Table 8. World Single-Domain Antibody Therapeutics Production Market Share by Region (2021-2026)
Table 9. World Single-Domain Antibody Therapeutics Production Market Share by Region (2027-2032)
Table 10. World Single-Domain Antibody Therapeutics Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Single-Domain Antibody Therapeutics Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Single-Domain Antibody Therapeutics Major Market Trends
Table 13. World Single-Domain Antibody Therapeutics Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Single-Domain Antibody Therapeutics Consumption by Region (2021-2026) & (K Units)
Table 15. World Single-Domain Antibody Therapeutics Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Single-Domain Antibody Therapeutics Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Single-Domain Antibody Therapeutics Producers in 2025
Table 18. World Single-Domain Antibody Therapeutics Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Single-Domain Antibody Therapeutics Producers in 2025
Table 20. World Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Single-Domain Antibody Therapeutics Company Evaluation Quadrant
Table 22. World Single-Domain Antibody Therapeutics Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Single-Domain Antibody Therapeutics Production Site of Key Manufacturer
Table 24. Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
Table 25. Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
Table 26. Single-Domain Antibody Therapeutics Competitive Factors
Table 27. Single-Domain Antibody Therapeutics New Entrant and Capacity Expansion Plans
Table 28. Single-Domain Antibody Therapeutics Mergers & Acquisitions Activity
Table 29. United States VS China Single-Domain Antibody Therapeutics Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Single-Domain Antibody Therapeutics Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Single-Domain Antibody Therapeutics Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share (2021-2026)
Table 37. China Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Single-Domain Antibody Therapeutics Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Single-Domain Antibody Therapeutics Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Single-Domain Antibody Therapeutics Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share (2021-2026)
Table 42. Rest of World Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share (2021-2026)
Table 47. World Single-Domain Antibody Therapeutics Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Single-Domain Antibody Therapeutics Production by Type (2021-2026) & (K Units)
Table 49. World Single-Domain Antibody Therapeutics Production by Type (2027-2032) & (K Units)
Table 50. World Single-Domain Antibody Therapeutics Production Value by Type (2021-2026) & (USD Million)
Table 51. World Single-Domain Antibody Therapeutics Production Value by Type (2027-2032) & (USD Million)
Table 52. World Single-Domain Antibody Therapeutics Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Single-Domain Antibody Therapeutics Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Single-Domain Antibody Therapeutics Production Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 55. World Single-Domain Antibody Therapeutics Production by Administration Route (2021-2026) & (K Units)
Table 56. World Single-Domain Antibody Therapeutics Production by Administration Route (2027-2032) & (K Units)
Table 57. World Single-Domain Antibody Therapeutics Production Value by Administration Route (2021-2026) & (USD Million)
Table 58. World Single-Domain Antibody Therapeutics Production Value by Administration Route (2027-2032) & (USD Million)
Table 59. World Single-Domain Antibody Therapeutics Average Price by Administration Route (2021-2026) & (US$/Unit)
Table 60. World Single-Domain Antibody Therapeutics Average Price by Administration Route (2027-2032) & (US$/Unit)
Table 61. World Single-Domain Antibody Therapeutics Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 62. World Single-Domain Antibody Therapeutics Production by Sales Channels (2021-2026) & (K Units)
Table 63. World Single-Domain Antibody Therapeutics Production by Sales Channels (2027-2032) & (K Units)
Table 64. World Single-Domain Antibody Therapeutics Production Value by Sales Channels (2021-2026) & (USD Million)
Table 65. World Single-Domain Antibody Therapeutics Production Value by Sales Channels (2027-2032) & (USD Million)
Table 66. World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2021-2026) & (US$/Unit)
Table 67. World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2027-2032) & (US$/Unit)
Table 68. World Single-Domain Antibody Therapeutics Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Single-Domain Antibody Therapeutics Production by Application (2021-2026) & (K Units)
Table 70. World Single-Domain Antibody Therapeutics Production by Application (2027-2032) & (K Units)
Table 71. World Single-Domain Antibody Therapeutics Production Value by Application (2021-2026) & (USD Million)
Table 72. World Single-Domain Antibody Therapeutics Production Value by Application (2027-2032) & (USD Million)
Table 73. World Single-Domain Antibody Therapeutics Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Single-Domain Antibody Therapeutics Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Sanofi Basic Information, Manufacturing Base and Competitors
Table 76. Sanofi Major Business
Table 77. Sanofi Single-Domain Antibody Therapeutics Product and Services
Table 78. Sanofi Single-Domain Antibody Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Sanofi Recent Developments/Updates
Table 80. Sanofi Competitive Strengths & Weaknesses
Table 81. Taisho Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 82. Taisho Pharmaceutical Major Business
Table 83. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
Table 84. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Taisho Pharmaceutical Recent Developments/Updates
Table 86. Taisho Pharmaceutical Competitive Strengths & Weaknesses
Table 87. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 88. Alphamab Oncology Major Business
Table 89. Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
Table 90. Alphamab Oncology Single-Domain Antibody Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Alphamab Oncology Recent Developments/Updates
Table 92. Alphamab Oncology Competitive Strengths & Weaknesses
Table 93. Global Key Players of Single-Domain Antibody Therapeutics Upstream (Raw Materials)
Table 94. Global Single-Domain Antibody Therapeutics Typical Customers
Table 95. Single-Domain Antibody Therapeutics Typical Distributors
Table 1. World Single-Domain Antibody Therapeutics Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Single-Domain Antibody Therapeutics Production Value by Region (2021-2026) & (USD Million)
Table 3. World Single-Domain Antibody Therapeutics Production Value by Region (2027-2032) & (USD Million)
Table 4. World Single-Domain Antibody Therapeutics Production Value Market Share by Region (2021-2026)
Table 5. World Single-Domain Antibody Therapeutics Production Value Market Share by Region (2027-2032)
Table 6. World Single-Domain Antibody Therapeutics Production by Region (2021-2026) & (K Units)
Table 7. World Single-Domain Antibody Therapeutics Production by Region (2027-2032) & (K Units)
Table 8. World Single-Domain Antibody Therapeutics Production Market Share by Region (2021-2026)
Table 9. World Single-Domain Antibody Therapeutics Production Market Share by Region (2027-2032)
Table 10. World Single-Domain Antibody Therapeutics Average Price by Region (2021-2026) & (US$/Unit)
Table 11. World Single-Domain Antibody Therapeutics Average Price by Region (2027-2032) & (US$/Unit)
Table 12. Single-Domain Antibody Therapeutics Major Market Trends
Table 13. World Single-Domain Antibody Therapeutics Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Units)
Table 14. World Single-Domain Antibody Therapeutics Consumption by Region (2021-2026) & (K Units)
Table 15. World Single-Domain Antibody Therapeutics Consumption Forecast by Region (2027-2032) & (K Units)
Table 16. World Single-Domain Antibody Therapeutics Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Single-Domain Antibody Therapeutics Producers in 2025
Table 18. World Single-Domain Antibody Therapeutics Production by Manufacturer (2021-2026) & (K Units)
Table 19. Production Market Share of Key Single-Domain Antibody Therapeutics Producers in 2025
Table 20. World Single-Domain Antibody Therapeutics Average Price by Manufacturer (2021-2026) & (US$/Unit)
Table 21. Global Single-Domain Antibody Therapeutics Company Evaluation Quadrant
Table 22. World Single-Domain Antibody Therapeutics Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Single-Domain Antibody Therapeutics Production Site of Key Manufacturer
Table 24. Single-Domain Antibody Therapeutics Market: Company Product Type Footprint
Table 25. Single-Domain Antibody Therapeutics Market: Company Product Application Footprint
Table 26. Single-Domain Antibody Therapeutics Competitive Factors
Table 27. Single-Domain Antibody Therapeutics New Entrant and Capacity Expansion Plans
Table 28. Single-Domain Antibody Therapeutics Mergers & Acquisitions Activity
Table 29. United States VS China Single-Domain Antibody Therapeutics Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Single-Domain Antibody Therapeutics Production Comparison, (2021 & 2025 & 2032) & (K Units)
Table 31. United States VS China Single-Domain Antibody Therapeutics Consumption Comparison, (2021 & 2025 & 2032) & (K Units)
Table 32. United States Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Single-Domain Antibody Therapeutics Production (2021-2026) & (K Units)
Table 36. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share (2021-2026)
Table 37. China Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Single-Domain Antibody Therapeutics Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Single-Domain Antibody Therapeutics Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Single-Domain Antibody Therapeutics Production, (2021-2026) & (K Units)
Table 41. China Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share (2021-2026)
Table 42. Rest of World Based Single-Domain Antibody Therapeutics Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production, (2021-2026) & (K Units)
Table 46. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share (2021-2026)
Table 47. World Single-Domain Antibody Therapeutics Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Single-Domain Antibody Therapeutics Production by Type (2021-2026) & (K Units)
Table 49. World Single-Domain Antibody Therapeutics Production by Type (2027-2032) & (K Units)
Table 50. World Single-Domain Antibody Therapeutics Production Value by Type (2021-2026) & (USD Million)
Table 51. World Single-Domain Antibody Therapeutics Production Value by Type (2027-2032) & (USD Million)
Table 52. World Single-Domain Antibody Therapeutics Average Price by Type (2021-2026) & (US$/Unit)
Table 53. World Single-Domain Antibody Therapeutics Average Price by Type (2027-2032) & (US$/Unit)
Table 54. World Single-Domain Antibody Therapeutics Production Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Table 55. World Single-Domain Antibody Therapeutics Production by Administration Route (2021-2026) & (K Units)
Table 56. World Single-Domain Antibody Therapeutics Production by Administration Route (2027-2032) & (K Units)
Table 57. World Single-Domain Antibody Therapeutics Production Value by Administration Route (2021-2026) & (USD Million)
Table 58. World Single-Domain Antibody Therapeutics Production Value by Administration Route (2027-2032) & (USD Million)
Table 59. World Single-Domain Antibody Therapeutics Average Price by Administration Route (2021-2026) & (US$/Unit)
Table 60. World Single-Domain Antibody Therapeutics Average Price by Administration Route (2027-2032) & (US$/Unit)
Table 61. World Single-Domain Antibody Therapeutics Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Table 62. World Single-Domain Antibody Therapeutics Production by Sales Channels (2021-2026) & (K Units)
Table 63. World Single-Domain Antibody Therapeutics Production by Sales Channels (2027-2032) & (K Units)
Table 64. World Single-Domain Antibody Therapeutics Production Value by Sales Channels (2021-2026) & (USD Million)
Table 65. World Single-Domain Antibody Therapeutics Production Value by Sales Channels (2027-2032) & (USD Million)
Table 66. World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2021-2026) & (US$/Unit)
Table 67. World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2027-2032) & (US$/Unit)
Table 68. World Single-Domain Antibody Therapeutics Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Single-Domain Antibody Therapeutics Production by Application (2021-2026) & (K Units)
Table 70. World Single-Domain Antibody Therapeutics Production by Application (2027-2032) & (K Units)
Table 71. World Single-Domain Antibody Therapeutics Production Value by Application (2021-2026) & (USD Million)
Table 72. World Single-Domain Antibody Therapeutics Production Value by Application (2027-2032) & (USD Million)
Table 73. World Single-Domain Antibody Therapeutics Average Price by Application (2021-2026) & (US$/Unit)
Table 74. World Single-Domain Antibody Therapeutics Average Price by Application (2027-2032) & (US$/Unit)
Table 75. Sanofi Basic Information, Manufacturing Base and Competitors
Table 76. Sanofi Major Business
Table 77. Sanofi Single-Domain Antibody Therapeutics Product and Services
Table 78. Sanofi Single-Domain Antibody Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Sanofi Recent Developments/Updates
Table 80. Sanofi Competitive Strengths & Weaknesses
Table 81. Taisho Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 82. Taisho Pharmaceutical Major Business
Table 83. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Product and Services
Table 84. Taisho Pharmaceutical Single-Domain Antibody Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Taisho Pharmaceutical Recent Developments/Updates
Table 86. Taisho Pharmaceutical Competitive Strengths & Weaknesses
Table 87. Alphamab Oncology Basic Information, Manufacturing Base and Competitors
Table 88. Alphamab Oncology Major Business
Table 89. Alphamab Oncology Single-Domain Antibody Therapeutics Product and Services
Table 90. Alphamab Oncology Single-Domain Antibody Therapeutics Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Alphamab Oncology Recent Developments/Updates
Table 92. Alphamab Oncology Competitive Strengths & Weaknesses
Table 93. Global Key Players of Single-Domain Antibody Therapeutics Upstream (Raw Materials)
Table 94. Global Single-Domain Antibody Therapeutics Typical Customers
Table 95. Single-Domain Antibody Therapeutics Typical Distributors
LIST OF FIGURES
Figure 1. Single-Domain Antibody Therapeutics Picture
Figure 2. World Single-Domain Antibody Therapeutics Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Single-Domain Antibody Therapeutics Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 5. World Single-Domain Antibody Therapeutics Average Price (2021-2032) & (US$/Unit)
Figure 6. World Single-Domain Antibody Therapeutics Production Value Market Share by Region (2021-2032)
Figure 7. World Single-Domain Antibody Therapeutics Production Market Share by Region (2021-2032)
Figure 8. North America Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 9. Europe Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 10. China Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 11. Japan Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 12. Single-Domain Antibody Therapeutics Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 15. World Single-Domain Antibody Therapeutics Consumption Market Share by Region (2021-2032)
Figure 16. United States Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 17. China Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 18. Europe Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 19. Japan Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 20. South Korea Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 21. ASEAN Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 22. India Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of Single-Domain Antibody Therapeutics by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Single-Domain Antibody Therapeutics Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Single-Domain Antibody Therapeutics Markets in 2025
Figure 26. United States VS China: Single-Domain Antibody Therapeutics Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Single-Domain Antibody Therapeutics Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Single-Domain Antibody Therapeutics Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share 2025
Figure 30. China Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share 2025
Figure 32. World Single-Domain Antibody Therapeutics Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Single-Domain Antibody Therapeutics Production Value Market Share by Type in 2025
Figure 34. Cablivi
Figure 35. Nanozora
Figure 36. Envafolimab
Figure 37. World Single-Domain Antibody Therapeutics Production Market Share by Type (2021-2032)
Figure 38. World Single-Domain Antibody Therapeutics Production Value Market Share by Type (2021-2032)
Figure 39. World Single-Domain Antibody Therapeutics Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Single-Domain Antibody Therapeutics Production Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 41. World Single-Domain Antibody Therapeutics Production Value Market Share by Administration Route in 2025
Figure 42. Subcutaneous Injection
Figure 43. Intravenous Injection
Figure 44. Other
Figure 45. World Single-Domain Antibody Therapeutics Production Market Share by Administration Route (2021-2032)
Figure 46. World Single-Domain Antibody Therapeutics Production Value Market Share by Administration Route (2021-2032)
Figure 47. World Single-Domain Antibody Therapeutics Average Price by Administration Route (2021-2032) & (US$/Unit)
Figure 48. World Single-Domain Antibody Therapeutics Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 49. World Single-Domain Antibody Therapeutics Production Value Market Share by Sales Channels in 2025
Figure 50. Online Sales
Figure 51. Offline Sales
Figure 52. World Single-Domain Antibody Therapeutics Production Market Share by Sales Channels (2021-2032)
Figure 53. World Single-Domain Antibody Therapeutics Production Value Market Share by Sales Channels (2021-2032)
Figure 54. World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2021-2032) & (US$/Unit)
Figure 55. World Single-Domain Antibody Therapeutics Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Single-Domain Antibody Therapeutics Production Value Market Share by Application in 2025
Figure 57. Hospital
Figure 58. Clinic
Figure 59. Others
Figure 60. World Single-Domain Antibody Therapeutics Production Market Share by Application (2021-2032)
Figure 61. World Single-Domain Antibody Therapeutics Production Value Market Share by Application (2021-2032)
Figure 62. World Single-Domain Antibody Therapeutics Average Price by Application (2021-2032) & (US$/Unit)
Figure 63. Single-Domain Antibody Therapeutics Industry Chain
Figure 64. Single-Domain Antibody Therapeutics Procurement Model
Figure 65. Single-Domain Antibody Therapeutics Sales Model
Figure 66. Single-Domain Antibody Therapeutics Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
Figure 1. Single-Domain Antibody Therapeutics Picture
Figure 2. World Single-Domain Antibody Therapeutics Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Single-Domain Antibody Therapeutics Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 5. World Single-Domain Antibody Therapeutics Average Price (2021-2032) & (US$/Unit)
Figure 6. World Single-Domain Antibody Therapeutics Production Value Market Share by Region (2021-2032)
Figure 7. World Single-Domain Antibody Therapeutics Production Market Share by Region (2021-2032)
Figure 8. North America Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 9. Europe Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 10. China Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 11. Japan Single-Domain Antibody Therapeutics Production (2021-2032) & (K Units)
Figure 12. Single-Domain Antibody Therapeutics Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 15. World Single-Domain Antibody Therapeutics Consumption Market Share by Region (2021-2032)
Figure 16. United States Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 17. China Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 18. Europe Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 19. Japan Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 20. South Korea Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 21. ASEAN Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 22. India Single-Domain Antibody Therapeutics Consumption (2021-2032) & (K Units)
Figure 23. Producer Shipments of Single-Domain Antibody Therapeutics by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Single-Domain Antibody Therapeutics Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Single-Domain Antibody Therapeutics Markets in 2025
Figure 26. United States VS China: Single-Domain Antibody Therapeutics Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Single-Domain Antibody Therapeutics Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Single-Domain Antibody Therapeutics Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share 2025
Figure 30. China Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Single-Domain Antibody Therapeutics Production Market Share 2025
Figure 32. World Single-Domain Antibody Therapeutics Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Single-Domain Antibody Therapeutics Production Value Market Share by Type in 2025
Figure 34. Cablivi
Figure 35. Nanozora
Figure 36. Envafolimab
Figure 37. World Single-Domain Antibody Therapeutics Production Market Share by Type (2021-2032)
Figure 38. World Single-Domain Antibody Therapeutics Production Value Market Share by Type (2021-2032)
Figure 39. World Single-Domain Antibody Therapeutics Average Price by Type (2021-2032) & (US$/Unit)
Figure 40. World Single-Domain Antibody Therapeutics Production Value by Administration Route, (USD Million), 2021 & 2025 & 2032
Figure 41. World Single-Domain Antibody Therapeutics Production Value Market Share by Administration Route in 2025
Figure 42. Subcutaneous Injection
Figure 43. Intravenous Injection
Figure 44. Other
Figure 45. World Single-Domain Antibody Therapeutics Production Market Share by Administration Route (2021-2032)
Figure 46. World Single-Domain Antibody Therapeutics Production Value Market Share by Administration Route (2021-2032)
Figure 47. World Single-Domain Antibody Therapeutics Average Price by Administration Route (2021-2032) & (US$/Unit)
Figure 48. World Single-Domain Antibody Therapeutics Production Value by Sales Channels, (USD Million), 2021 & 2025 & 2032
Figure 49. World Single-Domain Antibody Therapeutics Production Value Market Share by Sales Channels in 2025
Figure 50. Online Sales
Figure 51. Offline Sales
Figure 52. World Single-Domain Antibody Therapeutics Production Market Share by Sales Channels (2021-2032)
Figure 53. World Single-Domain Antibody Therapeutics Production Value Market Share by Sales Channels (2021-2032)
Figure 54. World Single-Domain Antibody Therapeutics Average Price by Sales Channels (2021-2032) & (US$/Unit)
Figure 55. World Single-Domain Antibody Therapeutics Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Single-Domain Antibody Therapeutics Production Value Market Share by Application in 2025
Figure 57. Hospital
Figure 58. Clinic
Figure 59. Others
Figure 60. World Single-Domain Antibody Therapeutics Production Market Share by Application (2021-2032)
Figure 61. World Single-Domain Antibody Therapeutics Production Value Market Share by Application (2021-2032)
Figure 62. World Single-Domain Antibody Therapeutics Average Price by Application (2021-2032) & (US$/Unit)
Figure 63. Single-Domain Antibody Therapeutics Industry Chain
Figure 64. Single-Domain Antibody Therapeutics Procurement Model
Figure 65. Single-Domain Antibody Therapeutics Sales Model
Figure 66. Single-Domain Antibody Therapeutics Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
